Disclosure Of Interests In Other Entities [Text Block]

Hyloris Pharmaceuticals SA - Filing #3166255

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31
Disclosure of interests in other entities [text block]	—	—	—	—	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	—	6	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Current assets	50,801,000 EUR	—	—	53,959,000 EUR	—	—	—	—	—	—	—
Non-current assets	11,063,000 EUR	—	—	9,485,000 EUR	—	—	—	—	—	—	—
Current liabilities	5,772,000 EUR	—	—	14,978,000 EUR	—	—	—	—	—	—	—
Non-current liabilities	1,047,000 EUR	—	—	409,000 EUR	—	—	—	—	—	—	—
Revenue	—	2,951,000 EUR	—	—	—	—	—	—	3,096,000 EUR	—	—
Profit (loss)	—	10,770,000 EUR	—	—	—	—	—	—	11,579,000 EUR	—	—
Comprehensive income	—	10,770,000 EUR	10,770,000 EUR	—	- EUR	- EUR	- EUR	- EUR	11,579,000 EUR	11,579,000 EUR	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Other comprehensive income	—	- EUR	—	—	—	—	—	—	- EUR	—	—
Investments accounted for using equity method	3,948,000 EUR	—	—	4,079,000 EUR	—	—	—	—	—	—	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	43,457,000 EUR	—	—	50,012,000 EUR	—	—	—	—	—	—	64,399,000 EUR
Other current financial liabilities	3,212,000 EUR	—	—	11,815,000 EUR	—	—	—	—	—	—	—
Other non-current financial liabilities	300,000 EUR	—	—	300,000 EUR	—	—	—	—	—	—	—
Tax expense (income)	—	4,000 EUR	—	—	—	—	—	—	297,000 EUR	—	—